Evidence map›Paper›PMID 41977352›Full record

ArticleInternational journal of molecular sciences2026

Quaternary Phosphonium Salts Outperformed Vemurafenib (PLX) and Etoposide Against BRAF

Silvana Alfei, Maria Grazia Signorello, Sara Tirendi, Elaheh Khaledizadeh, Paolo Giordani, Caterina Reggio, Barbara Marengo, Cinzia Domenicotti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvana AlfeiDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.ORCID 0000-0002-4630-4371
Maria Grazia SignorelloDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.
Sara TirendiDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0003-2384-0072
Elaheh KhaledizadehDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0009-0003-7390-916X
Paolo GiordaniDepartment of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.
Caterina ReggioLaboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini 5, 16147 Genoa, Italy.
Barbara MarengoDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0003-3056-6569
Cinzia DomenicottiDepartment of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy.ORCID 0000-0002-5003-7333

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late-stage metastatic cutaneous melanoma (MCM) and neuroblastoma (NB) are the most aggressive skin and childhood cancers with survival rates of <50%, mainly due to the emergence of resistance to available drugs, thus requiring an urgent solution. Quaternary phosphonium salts (QPSs) can exhibit strong anticancer effects, regardless of the developed resistance. Triphenyl (

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmEtoposideMelanomaNeuroblastomaOrganophosphorus CompoundsProto-Oncogene Proteins B-rafVemurafenib3T3 CellsAnimalsCell Line, TumorCell SurvivalHaCaT CellsHumansMiceAntineoplastic AgentsEtoposideOrganophosphorus CompoundsProto-Oncogene Proteins B-rafVemurafenibcell viability (%)cytotoxicity on HaCaT and 3T3 cellshaemolytic effectshigh-risk neuroblastoma (HR-NB)metastatic cutaneous melanoma (MCM)micro vesiclesquaternized phosphonium salts (QPSs)

Identifiers

PMID41977352
PMCPMC13072898

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.